Theravance Biopharma, Inc.
- Tickers
- TBPH
- Headquarters
- Not recorded
- SEC CIK
- 0001583107
- Website
- Not recorded
Closing prices
Too many attempts. Please wait a minute and try again.
Drugs
| Drug | Indications | Phase | Next catalyst | CT-VCA | Trials |
|---|---|---|---|---|---|
| Ampreloxetine | MSA - Multiple System Atrophy; Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | None scheduled | 1 |
FDA-approved applications
Too many attempts. Please wait a minute and try again.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
Too many attempts. Please wait a minute and try again.
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for Theravance Biopharma, Inc. on Insider TradesLast 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- 3 transactions, 13,314 shares, $226,737.42
- Other all other codes
- 31 transactions: grants, exercises, tax withholding, gifts and similar
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.